Pharmafile Logo

EndALS

keystone banner and screenshot

Genesis Research Group launches Keystone IEGP platform at ISPOR Europe 2026

Genesis Research Group (Genesis) launches Keystone, its modular platform for Integrated Evidence Generation Planning (IEGP), at ISPOR Europe 2026.

Genesis Research Group

- PMLiVE

Alexion and Aide Health launch app for people with rare diseases

More than 3.5 million people in the UK live with a rare condition

- PMLiVE

Shionogi to acquire IntraBio in deal worth $2bn

The deal will expand Shionogi’s growing portfolio with IntraBio’s rare diseases capabilities

- PMLiVE

Ogsiveo recommended by NICE to treat rare soft tissue tumours

Desmoid tumours are rare soft tissue tumours that can grow aggressively into nearby tissues

- PMLiVE

LEO Pharma acquires rights for dersimelagon from Tanabe Pharma

The company will pay $435m in up front and near-term milestone payments

- PMLiVE

LEO Pharma to acquire Replay gene therapy platform

The acquisition will advance innovation for patients with rare skin diseases

- PMLiVE

AL-S Pharma release new data from AP-101 phase 2 trial for ALS

ALS is a progressive neurodegenerative disease that affects the motor neurons of the brain and spinal cord

- PMLiVE

Shionogi starts phase 2 clinical trial for Pompe Disease

The rare disease affects around one in every 22,000 people worldwide

- PMLiVE

UCB’s Kygevvi receives positive CHMP opinion for thymidine kinase 2 deficiency

TK2d is an extremely rare disease characterised by severe and progressive muscle weakness

- PMLiVE

Sanofi announces positive results for venglustat in type 3 Gaucher disease

There are currently no approved treatments for the neurological symptoms of this disease

- PMLiVE

Havas Life London unveils AI awareness campaign

The campaign highlights the dangers of AI misinformation in rare disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links